Kakarla Nirupama, Zurawin Robert K
Department of Obstetrics and Gynecology, Division of Pediatric and Adolescent Gynecology, Baylor College of Medicine, Houston, Texas 77030, USA.
J Pediatr Adolesc Gynecol. 2006 Apr;19(2):125-9. doi: 10.1016/j.jpag.2006.01.050.
Progesterone-induced dermatitis is a rare disorder. It typically occurs in females due to an autoimmune phenomenon to endogenous progesterone production, but can also be caused by exogenous intake of a synthetic progestin. Here, we present a case of autoimmune progesterone dermatitis (AIPD) seen in an adolescent female.
The patient is a 15-year-old Caucasian female with no significant past medical history and no prior exogenous hormone use, who presented to her primary care physician complaining of cyclic skin eruptions. She noted that her dermatologic symptoms occurred monthly, just prior to her menses. An intradermal skin test using 0.1 cc of progesterone was performed. The patient immediately developed a wheal, confirming the diagnosis of AIPD. The patient was begun on a continuous regimen of an oral contraceptive pill with 30 micrograms of ethinyl estradiol and 0.15 mg of levonorgestrel. The skin eruptions have not returned since the initiation of this therapy.
Autoimmune progesterone dermatitis manifests via the occurrence of cyclic skin eruptions. Women with the disorder commonly present with dermatologic lesions in the luteal phase of the menstrual cycle. Diagnosis of AIPD is confirmed by performing a skin allergen test using progesterone. Due to its rarity, AIPD should be considered a diagnosis of exclusion. In cases believed to be due to an endogenous production of progesterone, several methods of therapy have been attempted. The ultimate goal of therapy is the suppression of ovulation, which will prevent endogenous hormone production as progesterone is only produced in ovulatory cycles. Currently, the first-line choice of therapy is a combination oral contraceptive. If this treatment is ineffective, patients have been treated with danazol, gonadotropin releasing hormone analogs, tamoxifen, and oophorectomy with varying success.
孕酮诱导的皮炎是一种罕见的疾病。它通常发生在女性身上,是由于对内源性孕酮产生的自身免疫现象,但也可能由外源性摄入合成孕激素引起。在此,我们报告一例青春期女性的自身免疫性孕酮皮炎(AIPD)病例。
患者为一名15岁的白种女性,既往无重大病史,也未使用过外源性激素,因周期性皮肤疹就诊于她的初级保健医生。她指出,她的皮肤病症状每月在月经前出现。使用0.1毫升孕酮进行了皮内皮肤试验。患者立即出现风团,确诊为AIPD。患者开始服用含30微克炔雌醇和0.15毫克左炔诺孕酮的复方口服避孕药。自开始这种治疗以来,皮肤疹未再出现。
自身免疫性孕酮皮炎通过周期性皮肤疹的出现表现出来。患有这种疾病的女性通常在月经周期的黄体期出现皮肤病变。通过使用孕酮进行皮肤过敏原试验可确诊AIPD。由于其罕见性,AIPD应被视为一种排除性诊断。在认为是由于内源性孕酮产生的病例中,已经尝试了几种治疗方法。治疗的最终目标是抑制排卵,这将防止内源性激素产生,因为孕酮仅在排卵周期中产生。目前,一线治疗选择是复方口服避孕药。如果这种治疗无效,患者已接受达那唑、促性腺激素释放激素类似物、他莫昔芬和卵巢切除术治疗,效果各异。